☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Gilead
Gilead Reports the US FDA’s Approval of sNDA for Vemlidy to Treat Hepatitis B Virus (HBV) Infection
April 1, 2024
Gilead and Xilio Therapeutics Join Forces to Develop XTX301 for the Treatment of Cancers
March 29, 2024
Gilead and Merck Report Results from the P-II Clinical Evaluation of Islatravir + Lenacapavir for HIV
March 7, 2024
Gilead and Compugen Sign an Exclusive License Agreement to Develop COM503, a Novel Pre-Clinical Immunotherapy Program
December 20, 2023
Gilead Entered into a 12-Year Partnership with Assembly Biosciences to Develop Novel Antiviral Therapies
October 18, 2023
Gilead Reports the US FDA’s Partial Clinical Hold on New Patient Enrolment of Magrolimab for Acute Myeloid Leukemia
August 22, 2023
Load more...
Back to Home